CD274 and breast cancer: Considering that PD‐L1 is overexpressed in BCG‐unresponsive tumors and is associated with BC stage progression,47 several anti‐PD‐L1 and antiprogrammed cell death protein 1 (PD‐1) drugs are being tested in patients with NMIBC who are refractory to BCG, or in patients with very high‐risk NMIBC and unexposed to BCG.